# Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

> **NCT06349837** · PHASE1 · RECRUITING · sponsor: **Sichuan University** · enrollment: 24 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Tislelizumab
- **RADIATION:** Low Dose Radiotherapy
- **RADIATION:** Stereotactic Ablative Radiotherapy

## Key facts

- **NCT ID:** NCT06349837
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-18
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-11-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06349837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06349837, "Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06349837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*